Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Luye Pharma to Acquire Swiss Patch Drug Assets for $269 Million

publication date: Jul 26, 2016
Luye Pharma will pay $269 million to acquire the transdermal patch and implant business of Swiss pharma Acino, a specialist in novel drug delivery systems. The agreement includes Acino's transdermal manufacturing operations, distribution, and R&D. Acino makes its own products and also operates a transdermanl patch drug CRO/CMO for outside customers. Luye's purchase is the latest example of China pharma's desire to move past collaborations with western pharmas and actually own assets in the EU and US. More details....

Stock Symbol: (HK: 2186)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital